Lambertus A L M Kiemeney
Overview
Explore the profile of Lambertus A L M Kiemeney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
5157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Starre C, Bangma C, Bijlsma M, van den Bergh A, Kiemeney L, Kievit W, et al.
BMC Cancer
. 2025 Jan;
25(1):149.
PMID: 39871169
Background: This paper describes the rationale and design of the RECOVER study. Currently, there is no consensus regarding the optimal treatment for high-risk, non-metastatic prostate cancer (PCa). The study primarily...
2.
Fluid intake and recurrence and progression risk of patients with non-muscle-invasive bladder cancer
Beeren I, Meijer H, van der Heijden A, Aben K, Witjes J, Kiemeney L, et al.
BJU Int
. 2025 Jan;
PMID: 39865397
Objectives: To evaluate the association of pre- and post-diagnosis fluid intake with non-muscle-invasive bladder cancer (NMIBC) recurrence and progression risk. Patients And Methods: Data were used from the multicentre prospective...
3.
Vrieling A, Olsson L, Kleuters G, Maurits J, Aben K, Sedelaar J, et al.
Cancer Causes Control
. 2025 Jan;
PMID: 39760894
Purpose: Obesity in mid-life is a well-established risk factor for developing renal cell carcinoma (RCC); however, patients with RCC who are obese at the time of diagnosis have more favorable...
4.
Oosterwijk-Wakka J, Houkes L, van der Zanden L, Kiemeney L, Junker K, Warren A, et al.
Neoplasia
. 2024 Dec;
60:101108.
PMID: 39724752
Introduction: Treatment with Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI) has increased the progression-free survival (PFS) and overall-survival (OS) of patients with metastasized renal cell carcinoma (mRCC). With...
5.
Vlaming M, Ausems M, Kiemeney L, Schijven G, van Melick H, Noordzij M, et al.
Prostate Cancer Prostatic Dis
. 2024 Dec;
PMID: 39639158
Background: International guidelines recommend germline genetic testing for men with metastatic prostate cancer. If offered to all patients by genetic healthcare professionals, there will be insufficient capacity to cope with...
6.
Vrieling A, Maurits J, Gerritsen J, Buffart L, Aben K, Sedelaar J, et al.
Support Care Cancer
. 2024 Nov;
32(12):800.
PMID: 39556130
Purpose: This study examined the associations of device-measured moderate-to-vigorous physical activity (MVPA) and sedentary time as well as self-reported MVPA with health-related quality of life (HRQoL) in patients with localized...
7.
Kiebach J, Beeren I, Aben K, Witjes J, van der Heijden A, Kiemeney L, et al.
Int J Cancer
. 2024 Nov;
156(8):1529-1540.
PMID: 39499231
Studies on the relationship of cigarette smoking with the risks of recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) are inconsistent and prospective data are scarce. Therefore, we aimed to...
8.
Beeren I, Koops C, van der Heijden A, Aben K, Kiemeney L, Witjes J, et al.
Bladder Cancer
. 2024 Nov;
10(3):215-220.
PMID: 39493821
Background: Not much is known about the extent to which urologists discuss lifestyle with patients with bladder cancer (BC), despite patients considering urologists as an important source of information and...
9.
Hof J, Vermeulen S, van der Heijden A, Verhaegh G, Dyrskjot L, Catto J, et al.
Bladder Cancer
. 2024 Jul;
9(1):59-71.
PMID: 38994482
Background: Various germline genetic variants are associated with the prognosis of non-muscle invasive bladder cancer (NMIBC). Germline variants in genes frequently somatically mutated in bladder cancer have not been studied...
10.